{"log_id": 2662480102011063064, "direction": 0, "words_result_num": 29, "words_result": [{"probability": {"variance": 0, "average": 0.900625, "min": 0.900625}, "location": {"width": 54, "top": 18, "height": 32, "left": 1150}, "words": "药"}, {"probability": {"variance": 0, "average": 0.999873, "min": 0.999873}, "location": {"width": 34, "top": 61, "height": 34, "left": 1159}, "words": "附"}, {"probability": {"variance": 0, "average": 0.999565, "min": 0.998561}, "location": {"width": 97, "top": 141, "height": 28, "left": 180}, "words": "药品名称"}, {"probability": {"variance": 1e-06, "average": 0.999104, "min": 0.997113}, "location": {"width": 272, "top": 185, "height": 35, "left": 174}, "words": "通用名称:注射用依那西普"}, {"probability": {"variance": 7.3e-05, "average": 0.993388, "min": 0.974801}, "location": {"width": 277, "top": 234, "height": 36, "left": 173}, "words": "商品名称:恩利( Enbrel)"}, {"probability": {"variance": 0.000438, "average": 0.986522, "min": 0.940765}, "location": {"width": 327, "top": 289, "height": 28, "left": 175}, "words": "英文名称: Etanercept for Injection"}, {"probability": {"variance": 0.000177, "average": 0.991441, "min": 0.961479}, "location": {"width": 302, "top": 337, "height": 32, "left": 172}, "words": "汉语拼音: Zhusheyong Yinaxip"}, {"probability": {"variance": 7.3e-05, "average": 0.990146, "min": 0.978232}, "location": {"width": 59, "top": 442, "height": 26, "left": 174}, "words": "[成份"}, {"probability": {"variance": 1e-06, "average": 0.999053, "min": 0.997267}, "location": {"width": 206, "top": 484, "height": 35, "left": 174}, "words": "主要成份:依那西普"}, {"probability": {"variance": 4e-05, "average": 0.995749, "min": 0.976536}, "location": {"width": 394, "top": 530, "height": 37, "left": 176}, "words": "辅料:甘露醇、蔗糖和氨丁三醇(Tris)"}, {"probability": {"variance": 0.00027, "average": 0.995668, "min": 0.895882}, "location": {"width": 863, "top": 565, "height": 52, "left": 173}, "words": "活性成份来源:依那西普是利用中国仓鼠卵巢(CHO)细胞表达系统产生的人肿瘤坏死"}, {"probability": {"variance": 0.000311, "average": 0.991143, "min": 0.90236}, "location": {"width": 862, "top": 615, "height": 51, "left": 174}, "words": "因子受体p75Fc融合蛋白。二聚体由人肿瘤坏死因子受体2(TNFR2/p75)的胞外配体"}, {"probability": {"variance": 0.002033, "average": 0.984344, "min": 0.736621}, "location": {"width": 866, "top": 664, "height": 53, "left": 173}, "words": "结合部位与人IgG1的Fc片段连接组成。组成依那西普的Fc包括Cn2、Cn3及连接部"}, {"probability": {"variance": 0.010589, "average": 0.964171, "min": 0.441861}, "location": {"width": 863, "top": 714, "height": 50, "left": 175}, "words": "位,但不包括IgG1的Cn1部分。通过检测依那西普中和INFα介导A375细胞的成长"}, {"probability": {"variance": 0.000128, "average": 0.994693, "min": 0.940406}, "location": {"width": 670, "top": 768, "height": 45, "left": 174}, "words": "抑制作用确定依那西普的效能,依那西普的活性为1.7×10单位/mg"}, {"probability": {"variance": 0.00015, "average": 0.994813, "min": 0.938916}, "location": {"width": 573, "top": 818, "height": 45, "left": 176}, "words": "分子量:依那西普包括934个氨基酸,分子量约为150kD"}, {"probability": {"variance": 0.000151, "average": 0.991148, "min": 0.973792}, "location": {"width": 54, "top": 929, "height": 27, "left": 183}, "words": "性状]"}, {"probability": {"variance": 5.9e-05, "average": 0.997001, "min": 0.968364}, "location": {"width": 374, "top": 967, "height": 41, "left": 222}, "words": "白色冻干粉。溶剂为澄清、无色液体"}, {"probability": {"variance": 1e-06, "average": 0.998311, "min": 0.99674}, "location": {"width": 71, "top": 1076, "height": 25, "left": 185}, "words": "适应症"}, {"probability": {"variance": 0, "average": 0.999373, "min": 0.999026}, "location": {"width": 128, "top": 1067, "height": 51, "left": 727}, "words": "药经"}, {"probability": {"variance": 8.5e-05, "average": 0.994316, "min": 0.969867}, "location": {"width": 206, "top": 1120, "height": 28, "left": 177}, "words": "类风湿关节炎(RA)"}, {"probability": {"variance": 5.5e-05, "average": 0.997327, "min": 0.955467}, "location": {"width": 822, "top": 1152, "height": 48, "left": 223}, "words": "中度至重度活动性类风湿关节炎的成年患者对包括甲氨蝶呤(如果不禁忌使用)在"}, {"probability": {"variance": 3.6e-05, "average": 0.996995, "min": 0.96818}, "location": {"width": 829, "top": 1202, "height": 48, "left": 176}, "words": "内的 DMARD(改善病情的抗风湿药)无效时,可用依那西普与甲氨蝶呤联用治疗"}, {"probability": {"variance": 0.000212, "average": 0.994677, "min": 0.930052}, "location": {"width": 825, "top": 1251, "height": 47, "left": 223}, "words": "已证实依那西普单独使用或与甲氨蝶呤联用时,可降低X线检测相的关节损害进展"}, {"probability": {"variance": 3e-06, "average": 0.998854, "min": 0.995549}, "location": {"width": 209, "top": 1315, "height": 31, "left": 175}, "words": "率,并改善关节功能"}, {"probability": {"variance": 0.000308, "average": 0.988832, "min": 0.945838}, "location": {"width": 203, "top": 1414, "height": 28, "left": 177}, "words": "强直性脊柱炎(AS)"}, {"probability": {"variance": 3e-06, "average": 0.998935, "min": 0.993944}, "location": {"width": 762, "top": 1448, "height": 46, "left": 223}, "words": "重度活动性强直性脊柱炎的成年患者对常规治疗无效时可使用依那西普治疗"}, {"probability": {"variance": 3.5e-05, "average": 0.995619, "min": 0.97788}, "location": {"width": 170, "top": 1611, "height": 25, "left": 177}, "words": "版本号:20090118"}, {"probability": {"variance": 8e-06, "average": 0.997529, "min": 0.993336}, "location": {"width": 170, "top": 1594, "height": 33, "left": 797}, "words": "第2页共31页"}], "language": 3}